Top Tweets for #FP100

For decades, endometriosis has been one of the most mysterious and debilitating conditions affecting millions of women worldwide, causing chronic pain, infertility, and reduced quality of life. Now, a major study suggests that a common bacterium may play a key role in driving the disease. Researchers identified Fusobacterium (particularly Fusobacterium nucleatum), a bacterium frequently found in the mouth and gut, in the uterine lining of approximately 64% of women with endometriosis — compared to less than 10% of healthy controls. Once present, the infection appears to trigger the release of a signaling protein called TGF-β, which causes normal endometrial fibroblasts to transform into aggressive myofibroblasts that promote the growth and spread of endometriotic lesions. This discovery raises exciting possibilities for new, non-hormonal treatments. In mouse models of endometriosis, antibiotic therapy targeting Fusobacterium (such as metronidazole) significantly reduced both the number and size of lesions. While these results are promising, the authors emphasize that further clinical trials are needed to confirm whether eradicating the bacterium can effectively treat the condition in humans. The findings represent a significant step forward in understanding the microbial contributions to endometriosis and could pave the way for more targeted, less invasive therapies beyond current options like surgery and hormonal suppression. [Muraoka, A., et al. (2023). "Fusobacterium infection facilitates the development of endometriosis through the phenotypic transition of endometrial fibroblasts." Science Translational Medicine, 15(700). DOI: 10.1126/scitranslmed.add1531]